114 related articles for article (PubMed ID: 2390716)
1. Transport into brain of buthionine sulfoximine, an inhibitor of glutathione synthesis, is facilitated by esterification and administration of dimethylsulfoxide.
Steinherz R; Mårtensson J; Wellner D; Meister A
Brain Res; 1990 Jun; 518(1-2):115-9. PubMed ID: 2390716
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of buthionine sulfoximine (NSC 326231) and its effect on melphalan-induced toxicity in mice.
Smith AC; Liao JT; Page JG; Wientjes MG; Grieshaber CK
Cancer Res; 1989 Oct; 49(19):5385-91. PubMed ID: 2766304
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of glutathione synthesis in the liver leads to S-adenosyl-L-methionine synthetase reduction.
Corrales F; Ochoa P; Rivas C; Martin-Lomas M; Mato JM; Pajares MA
Hepatology; 1991 Sep; 14(3):528-33. PubMed ID: 1874498
[TBL] [Abstract][Full Text] [Related]
4. Effects of chronic inhibition of glutathione biosynthesis on cholesterol and bile acid metabolism in rats.
Hassan AS
Biochim Biophys Acta; 1988 Nov; 963(2):131-8. PubMed ID: 3196722
[TBL] [Abstract][Full Text] [Related]
5. Effects of buthionine sulfoximine on the development of ozone-induced pulmonary fibrosis.
Sun JD; Pickrell JA; Harkema JR; McLaughlin SI; Hahn FF; Henderson RF
Exp Mol Pathol; 1988 Oct; 49(2):254-66. PubMed ID: 2901982
[TBL] [Abstract][Full Text] [Related]
6. Protection from hyperbaric oxidant stress by administration of buthionine sulfoximine.
Komadina KH; Duncan CA; Bryan CL; Jenkinson SG
J Appl Physiol (1985); 1991 Jul; 71(1):352-8. PubMed ID: 1680846
[TBL] [Abstract][Full Text] [Related]
7. Rate of buthionine sulfoximine entry into brain and xenotransplanted human gliomas.
Fekete I; Griffith OW; Schlageter KE; Bigner DD; Friedman HS; Groothuis DR
Cancer Res; 1990 Feb; 50(4):1251-6. PubMed ID: 2297773
[TBL] [Abstract][Full Text] [Related]
8. Effect of buthionine sulfoximine, an inhibitor of glutathione biosynthesis, on the selenium-induced lethality in mice.
Ishikawa M; Takayanagi G; Sasaki K
Jpn J Pharmacol; 1988 Oct; 48(2):283-6. PubMed ID: 3210451
[TBL] [Abstract][Full Text] [Related]
9. Effects of buthionine sulfoximine treatment on cellular glutathione levels and cytotoxicities of cisplatin, carboplatin and radiation in human stomach and ovarian cancer cell lines.
Lee KS; Kim HK; Moon HS; Hong YS; Kang JH; Kim DJ; Park JG
Korean J Intern Med; 1992 Jul; 7(2):111-7. PubMed ID: 1306072
[TBL] [Abstract][Full Text] [Related]
10. Buthionine sulfoximine inhibition of glutathione biosynthesis enhances hepatic lipid peroxidation in rats during acute ethanol intoxication.
Kera Y; Ohbora Y; Komura S
Alcohol Alcohol; 1989; 24(6):519-24. PubMed ID: 2576368
[TBL] [Abstract][Full Text] [Related]
11. Glutathione levels in cultured heart cells. Influence of buthionine sulfoximine, an inhibitor of glutathione synthesis.
Lewko WM
Biochem Pharmacol; 1987 Jan; 36(2):219-23. PubMed ID: 3814167
[TBL] [Abstract][Full Text] [Related]
12. Long-term buthionine-sulfoximine-mediated toxicity in cultured hepatoma cell lines.
Dierickx PJ
Res Commun Chem Pathol Pharmacol; 1990 Mar; 67(3):423-6. PubMed ID: 2160706
[TBL] [Abstract][Full Text] [Related]
13. Induction of rat UDP-glucuronosyltransferase and glutathione S-transferase activities by L-buthionine-S,R-sulfoximine without induction of cytochrome P-450.
Manning BW; Franklin MR
Toxicology; 1990 Dec; 65(1-2):149-59. PubMed ID: 2125759
[TBL] [Abstract][Full Text] [Related]
14. Buthionine sulfoximine-mediated depletion of glutathione in intracranial human glioma-derived xenografts.
Skapek SX; Colvin OM; Griffith OW; Groothuis DR; Colapinto EV; Lee Y; Hilton J; Elion GB; Bigner DD; Friedman HS
Biochem Pharmacol; 1988 Nov; 37(22):4313-7. PubMed ID: 3196356
[TBL] [Abstract][Full Text] [Related]
15. Pharmacodynamics of prolonged treatment with L,S-buthionine sulfoximine.
Malaker K; Hurwitz SJ; Bump EA; Griffith OW; Lai LL; Riese N; Coleman CN
Int J Radiat Oncol Biol Phys; 1994 May; 29(2):407-12. PubMed ID: 7910818
[TBL] [Abstract][Full Text] [Related]
16. Effect of buthionine sulfoximine on acute N-(3,5-dichlorophenyl)succinimide-induced nephrotoxicity in Fischer 344 rats.
Rankin GO; Teets VJ; Nicoll DW; Brown PI
Toxicol Lett; 1990 Jun; 52(1):91-100. PubMed ID: 2356574
[TBL] [Abstract][Full Text] [Related]
17. Time-dependent pharmacodynamic models in cancer chemotherapy: population pharmacodynamic model for glutathione depletion following modulation by buthionine sulfoximine (BSO) in a Phase I trial of melphalan and BSO.
Gallo JM; Brennan J; Hamilton TC; Halbherr T; Laub PB; Ozols RF; O'Dwyer PJ
Cancer Res; 1995 Oct; 55(20):4507-11. PubMed ID: 7553617
[TBL] [Abstract][Full Text] [Related]
18. The effect of L-buthionine-[S,R]-sulfoximine on the pancreas in mice. A model of weakening glutathione-based defense mechanisms.
Lüthen RE; Neuschwander-Tetri BA; Niederau C; Ferrell LD; Grendell JH
Int J Pancreatol; 1994 Aug; 16(1):31-6. PubMed ID: 7528760
[TBL] [Abstract][Full Text] [Related]
19. Depletion of brain glutathione in preweanling mice by L-buthionine sulfoximine.
Slivka A; Spina MB; Calvin HI; Cohen G
J Neurochem; 1988 May; 50(5):1391-3. PubMed ID: 3361302
[TBL] [Abstract][Full Text] [Related]
20. L-Buthionine (S,R) sulfoximine depletes hepatic glutathione but protects against ethanol-induced liver injury.
Donohue TM; Curry-McCoy TV; Todero SL; White RL; Kharbanda KK; Nanji AA; Osna NA
Alcohol Clin Exp Res; 2007 Jun; 31(6):1053-60. PubMed ID: 17428293
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
